Pharma injects ever more VC into biotech
In this issue:
Pharma looking to score with biotech innovation Just when it looked liked belts couldn't get any tighter in European venture capital circles, Big Pharma is filling funding gaps with "corporate venturing". Many pharma majors have set up largely autonomous units to provide VC to promising bio tech SMEs. On the surface, it looks like a win-win situation. Start-ups receive desperately needed cash, while pharma giants reap dividends for making the right bets, and receive options on what they desperately need - successful new drugs. But is it really that simple?